Norris Medicines Ltd

Norris Medicines has reached a new 52-week low of Rs.14, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial and market position.

Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning.

Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's current trading levels reflect ongoing pressures within the Trading & Distributors sector, contrasting with the broader market's relative strength.

Norris Medicines has reached a new 52-week low of Rs.14.5 today, marking a significant decline in its stock price amid continued underperformance relative to its sector and broader market indices.

Norris Medicines has reached a new 52-week low of Rs.14.5, marking a significant decline in its stock price as it continues to underperform relative to its sector and broader market indices. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning.

Norris Medicines Limited, the Ankleshwar-based pharmaceutical manufacturer and distributor, reported a troubling second quarter for FY2026, with net losses widening to ₹0.72 crores despite a 57.48% year-on-year revenue increase. The micro-cap company, valued at just ₹15.00 crores, continues to struggle with operational inefficiencies and negative profitability metrics that have plagued its performance for multiple quarters. Trading at ₹15.93 on November 18, 2025, the stock reflects investor scepticism about the company's ability to achieve sustainable profitability.

Norris Medicines Ltd is experiencing a surge in buying activity, with a notable increase today, reversing a previous decline. Over the past week and month, the stock has outperformed the Sensex. Despite recent challenges, it has shown significant long-term growth compared to the broader market.

Norris Medicines Ltd is experiencing notable buying activity, with a significant rise today after three days of decline. While the stock has faced challenges over the past year, it has shown resilience over five years. Today's performance indicates a potential shift in market sentiment and recovery.

Norris Medicines has announced its financial results for the quarter ending June 2025, revealing stable performance without significant fluctuations. The company's stock score has remained unchanged over the past three months, indicating consistent underlying financial conditions as it continues to operate in the trading and distribution sector.